# Centrus Energy Corp: financial statements, quarterly

LEU · NYSE · CIK 1065059 · [Materials](/sectors/materials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/leu.md) · [Financials](/companies/leu/financials.md) · [Filings](/companies/leu/filings.md) · [Insiders](/companies/leu/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/leu/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [51.3](/filings/0001065059-24-000089.md) | [104 d](/filings/0001628280-26-007117.md) | [43.7](/filings/0001065059-25-000024.md) | [189](/filings/0001065059-25-000058.md) | [57.7](/filings/0001628280-25-049844.md) | [152 d](/filings/0001628280-26-007117.md) | [73.1](/filings/0001628280-26-030891.md) | [155](/filings/0001628280-26-053863.md) | [74.9](/filings/0001628280-25-049844.md) | [146 d](/filings/0001628280-26-007117.md) | [76.7](/filings/0001628280-26-030891.md) | [176](/filings/0001628280-26-053863.md) |
| Cost of revenue | $m | [40.0](/filings/0001065059-24-000089.md) | [53.8 d](/filings/0001628280-26-007117.md) | [39.4](/filings/0001065059-25-000024.md) | [153](/filings/0001065059-25-000058.md) | [48.8](/filings/0001628280-25-049844.md) | [89.8 d](/filings/0001628280-26-007117.md) | [40.2](/filings/0001628280-26-030891.md) | [101](/filings/0001628280-26-053863.md) | [79.2](/filings/0001628280-25-049844.md) | [111 d](/filings/0001628280-26-007117.md) | [45.2](/filings/0001628280-26-030891.md) | [126](/filings/0001628280-26-053863.md) |
| Gross profit | $m | [11.3](/filings/0001065059-24-000089.md) | [49.8 d](/filings/0001628280-26-007117.md) | [4.3](/filings/0001065059-25-000024.md) | [36.5](/filings/0001065059-25-000058.md) | [8.9](/filings/0001628280-25-049844.md) | [61.8 d](/filings/0001628280-26-007117.md) | [32.9](/filings/0001628280-26-030891.md) | [53.9](/filings/0001628280-26-053863.md) | [(4.3)](/filings/0001628280-25-049844.md) | [35.0 d](/filings/0001628280-26-007117.md) | [31.5](/filings/0001628280-26-030891.md) | [49.9](/filings/0001628280-26-053863.md) |
| Research and development | $m | [3.3](/filings/0001065059-24-000089.md) | [3.4 d](/filings/0001628280-26-007117.md) | [5.7](/filings/0001065059-25-000024.md) | [4.1](/filings/0001065059-25-000058.md) | [4.1](/filings/0001628280-25-049844.md) | [3.3 d](/filings/0001628280-26-007117.md) | [3.0](/filings/0001628280-26-030891.md) | [3.3](/filings/0001628280-26-053863.md) | [1.7](/filings/0001628280-25-049844.md) | [8.9 d](/filings/0001628280-26-007117.md) | [18.9](/filings/0001628280-26-030891.md) | [10.8](/filings/0001628280-26-053863.md) |
| Selling, general and administrative | $m | [9.5](/filings/0001065059-24-000089.md) | [9.4 d](/filings/0001628280-26-007117.md) | [8.1](/filings/0001065059-25-000024.md) | [7.1](/filings/0001065059-25-000058.md) | [9.6](/filings/0001628280-25-049844.md) | [10.4 d](/filings/0001628280-26-007117.md) | [8.3](/filings/0001628280-26-030891.md) | [13.4](/filings/0001628280-26-053863.md) | [8.9](/filings/0001628280-25-049844.md) | [10.3 d](/filings/0001628280-26-007117.md) | [10.0](/filings/0001628280-26-030891.md) | [26.2](/filings/0001628280-26-053863.md) |
| Operating income | $m | [(2.9)](/filings/0001065059-24-000089.md) | [32.6 d](/filings/0001628280-26-007117.md) | [(10.6)](/filings/0001065059-25-000024.md) | [21.1](/filings/0001065059-25-000058.md) | [(7.6)](/filings/0001628280-25-049844.md) | [45.1 d](/filings/0001628280-26-007117.md) | [20.5](/filings/0001628280-26-030891.md) | [33.5](/filings/0001628280-26-053863.md) | [(16.6)](/filings/0001628280-25-049844.md) | [12.8 d](/filings/0001628280-26-007117.md) | [0.8](/filings/0001628280-26-030891.md) | [10.4](/filings/0001628280-26-053863.md) |
| Income tax | $m | [(7.6)](/filings/0001065059-24-000089.md) | [2.0 d](/filings/0001628280-26-007117.md) | [(2.3)](/filings/0001065059-25-000024.md) | [8.9](/filings/0001065059-25-000058.md) | [(0.9)](/filings/0001628280-25-049844.md) | [(5.9) d](/filings/0001628280-26-007117.md) | [8.0](/filings/0001628280-26-030891.md) | [8.5](/filings/0001628280-26-053863.md) | [(11.9)](/filings/0001628280-25-049844.md) | [3.5 d](/filings/0001628280-26-007117.md) | [2.5](/filings/0001628280-26-030891.md) | [4.8](/filings/0001628280-26-053863.md) |
| Net income | $m | [8.2](/filings/0001065059-24-000089.md) | [56.3 d](/filings/0001628280-26-007117.md) | [(6.1)](/filings/0001628280-25-049844.md) | [30.6](/filings/0001628280-25-049844.md) | [(5.0)](/filings/0001628280-25-049844.md) | [53.7 d](/filings/0001628280-26-007117.md) | [27.2](/filings/0001628280-26-053863.md) | [28.9](/filings/0001628280-26-053863.md) | [3.9](/filings/0001628280-25-049844.md) | [17.8 d](/filings/0001628280-26-007117.md) | [10.0](/filings/0001628280-26-053863.md) | [16.8](/filings/0001628280-26-053863.md) |
| Diluted EPS | $ per share | [0.52](/filings/0001065059-24-000089.md) | not reported | [(0.38)](/filings/0001065059-25-000024.md) | [1.89](/filings/0001065059-25-000058.md) | [(0.30)](/filings/0001628280-25-049844.md) | not reported | [1.60](/filings/0001628280-26-030891.md) | [1.59](/filings/0001628280-26-053863.md) | [0.19](/filings/0001628280-25-049844.md) | not reported | [0.45](/filings/0001628280-26-030891.md) | [0.77](/filings/0001628280-26-053863.md) |
| Basic EPS | $ per share | [0.53](/filings/0001065059-24-000089.md) | not reported | [(0.38)](/filings/0001065059-25-000024.md) | [1.89](/filings/0001065059-25-000058.md) | [(0.30)](/filings/0001628280-25-049844.md) | not reported | [1.60](/filings/0001628280-26-030891.md) | [1.63](/filings/0001628280-26-053863.md) | [0.21](/filings/0001628280-25-049844.md) | not reported | [0.51](/filings/0001628280-26-030891.md) | [0.85](/filings/0001628280-26-053863.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [183](/filings/0001065059-23-000072.md) | [201](/filings/0001065059-25-000006.md) | [209](/filings/0001065059-24-000031.md) | [227](/filings/0001065059-24-000074.md) | [194](/filings/0001065059-24-000089.md) | [671](/filings/0001628280-26-007117.md) | [653](/filings/0001065059-25-000024.md) | [833](/filings/0001065059-25-000058.md) | [1,632](/filings/0001628280-25-049844.md) | [1,957](/filings/0001628280-26-053863.md) | [1,868](/filings/0001628280-26-030891.md) | [1,869](/filings/0001628280-26-053863.md) |
| Current assets | $m | [532](/filings/0001065059-23-000072.md) | [685](/filings/0001065059-25-000006.md) | [657](/filings/0001065059-24-000031.md) | [593](/filings/0001065059-24-000074.md) | [517](/filings/0001065059-24-000089.md) | [1,015](/filings/0001628280-26-007117.md) | [1,223](/filings/0001065059-25-000024.md) | [1,251](/filings/0001065059-25-000058.md) | [2,165](/filings/0001628280-25-049844.md) | [2,364](/filings/0001628280-26-053863.md) | [2,295](/filings/0001628280-26-030891.md) | [2,317](/filings/0001628280-26-053863.md) |
| Total assets | $m | [645](/filings/0001065059-23-000072.md) | [796](/filings/0001065059-25-000006.md) | [750](/filings/0001065059-24-000031.md) | [668](/filings/0001065059-24-000074.md) | [591](/filings/0001065059-24-000089.md) | [1,093](/filings/0001628280-26-007117.md) | [1,294](/filings/0001065059-25-000024.md) | [1,315](/filings/0001065059-25-000058.md) | [2,245](/filings/0001628280-25-049844.md) | [2,446](/filings/0001628280-26-053863.md) | [2,433](/filings/0001628280-26-030891.md) | [2,531](/filings/0001628280-26-053863.md) |
| Current liabilities | $m | [337](/filings/0001065059-23-000072.md) | [471](/filings/0001065059-25-000006.md) | [455](/filings/0001065059-24-000031.md) | [390](/filings/0001065059-24-000074.md) | [317](/filings/0001065059-24-000089.md) | [347](/filings/0001628280-26-007117.md) | [578](/filings/0001065059-25-000024.md) | [482](/filings/0001065059-25-000058.md) | [626](/filings/0001628280-25-049844.md) | [423](/filings/0001628280-26-053863.md) | [401](/filings/0001628280-26-030891.md) | [430](/filings/0001628280-26-053863.md) |
| Total liabilities | $m | [669](/filings/0001065059-23-000072.md) | [764](/filings/0001065059-25-000006.md) | [716](/filings/0001065059-24-000031.md) | [592](/filings/0001065059-24-000074.md) | [515](/filings/0001065059-24-000089.md) | [932](/filings/0001628280-26-007117.md) | [1,080](/filings/0001065059-25-000024.md) | [956](/filings/0001065059-25-000058.md) | [1,882](/filings/0001628280-25-049844.md) | [1,681](/filings/0001628280-26-053863.md) | [1,658](/filings/0001628280-26-030891.md) | [1,686](/filings/0001628280-26-053863.md) |
| Long-term debt | $m | [89.6](/filings/0001065059-23-000072.md) | [89.6](/filings/0001065059-25-000006.md) | [86.5](/filings/0001065059-24-000031.md) | [86.5](/filings/0001065059-24-000074.md) | [83.5](/filings/0001065059-24-000089.md) | [473](/filings/0001628280-26-007117.md) | [390](/filings/0001065059-25-000024.md) | [390](/filings/0001065059-25-000058.md) | [1,174](/filings/0001628280-25-049844.md) | [1,175](/filings/0001628280-26-053863.md) | [1,176](/filings/0001628280-26-030891.md) | [1,178](/filings/0001628280-26-053863.md) |
| Current portion of debt | $m | [6.1](/filings/0001065059-23-000072.md) | [6.1](/filings/0001065059-25-000006.md) | [6.1](/filings/0001065059-24-000031.md) | [6.1](/filings/0001065059-24-000074.md) | [6.1](/filings/0001065059-24-000089.md) | [6.1](/filings/0001628280-26-007117.md) | [0.0](/filings/0001065059-25-000024.md) | [0.0](/filings/0001065059-25-000058.md) | [0.0](/filings/0001628280-25-049844.md) | [0.0](/filings/0001628280-26-053863.md) | [0.0](/filings/0001628280-26-030891.md) | [0.0](/filings/0001628280-26-053863.md) |
| Shareholders' equity | $m | [(24.0)](/filings/0001065059-24-000089.md) | [32.3](/filings/0001628280-26-007117.md) | [33.8](/filings/0001628280-25-049844.md) | [76.6](/filings/0001628280-25-049844.md) | [76.4](/filings/0001628280-25-049844.md) | [161](/filings/0001628280-26-053863.md) | [214](/filings/0001628280-26-053863.md) | [359](/filings/0001628280-26-053863.md) | [363](/filings/0001628280-25-049844.md) | [765](/filings/0001628280-26-053863.md) | [775](/filings/0001628280-26-053863.md) | [845](/filings/0001628280-26-053863.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Current portion of debt: us-gaap:DebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(24.0) d](/filings/0001065059-24-000089.md) | [17.9 d](/filings/0001628280-26-007117.md) | [5.3](/filings/0001065059-25-000024.md) | [7.0 d](/filings/0001065059-25-000058.md) | [(33.2) d](/filings/0001628280-25-049844.md) | [57.9 d](/filings/0001628280-26-007117.md) | [36.5](/filings/0001628280-26-030891.md) | [52.8 d](/filings/0001628280-26-053863.md) | [10.1 d](/filings/0001628280-25-049844.md) | [(48.4) d](/filings/0001628280-26-007117.md) | [(35.1)](/filings/0001628280-26-030891.md) | [18.4 d](/filings/0001628280-26-053863.md) |
| Capital expenditure | $m | [0.4 d](/filings/0001065059-24-000089.md) | [0.5 d](/filings/0001628280-26-007117.md) | [1.5](/filings/0001065059-25-000024.md) | [0.9 d](/filings/0001065059-25-000058.md) | [1.0 d](/filings/0001628280-25-049844.md) | [0.7 d](/filings/0001628280-26-007117.md) | [2.1](/filings/0001628280-26-030891.md) | [3.6 d](/filings/0001628280-26-053863.md) | [4.4 d](/filings/0001628280-25-049844.md) | [9.6 d](/filings/0001628280-26-007117.md) | [23.2](/filings/0001628280-26-030891.md) | [71.6 d](/filings/0001628280-26-053863.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [14.6](/filings/0001065059-23-000072.md) | [15.2](/filings/0001065059-24-000031.md) | [15.4](/filings/0001065059-24-000074.md) | [15.6](/filings/0001065059-24-000089.md) | [15.9](/filings/0001065059-25-000024.md) | [16.2](/filings/0001065059-25-000058.md) | [16.4](/filings/0001628280-25-049844.md) | [17.0](/filings/0001628280-26-030891.md) | [18.1](/filings/0001628280-26-053863.md) | [20.7](/filings/0001628280-25-049844.md) | [22.4](/filings/0001628280-26-030891.md) | [21.9](/filings/0001628280-26-053863.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 13,673,933 at 2022-03-01, from the cover of the [10-K filed 2022-03-11](/filings/0001065059-22-000012.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:32 ET. No prices; not investment advice.